Boehringer Ingelheim GmbH
- INGELHEIM, Germany|제약
Data from key trials will aid in increasing scientific understanding of ESUS and CVT
RESPECT-ESUS is first randomised trial to investigate clinical profile of Pradaxa® vs ASA
INGELHEIM, GERMANY--(Business Wire / Korea Newswire) October 15, 2018 -- Boehringer Ingelheim today announced that primary results from two key trials, RE-SPECT ESUS® and RE-SPECT CVT®, will be presented at the upcoming World Stroke Congress in Montreal, Canada 17-20 October 2018. These primary analyses will contribute to the scientific community’s understanding of both disease states and the clinical profile of dabigatran etexilate (Pradaxa®).
The results from RE-SPECT ESUS, the first randomised trial comparing dabigatran etexilate with acetylsalicylic acid (ASA) in any indication, will add further insight into the prevention of secondary stroke in patients with an embolic stroke of undetermined source (ESUS).1 As the first comparison to ASA, this trial will also offer further important insights into the clinical profile of dabigatran etexilate.
RE-SPECT CVT will provide additional knowledge regarding treatment of patients with cerebral venous thrombosis (CVT).2 It is the first exploratory, prospective, randomised controlled study of any non-vitamin K antagonist oral anticoagulant (NOAC) in patients with blood clots in the veins or venous sinuses of the brain.
Both trials are part of Boehringer Ingelheim’s ongoing commitment to expanding scientific knowledge of stroke prevention and form part of the extensive RE-VOLUTION® clinical trial programme for dabigatran etexilate, which upon completion will have enrolled more than 60,000 patients worldwide.1-14
The results from these two trials will be presented in the following sessions:
RE-SPECT ESUS: Dabigatran versus acetylsalicylic acid for stroke prevention in patients with embolic stroke of undetermined source
Wednesday 17 October, 19:10 - 19:30, HALL A
Session code: AWA01
Session title: Opening: late-breaking trials
Presentation number: 100
RE-SPECT CVT: Randomized controlled trial of the safety and efficacy of dabigatran etexilate vs. dose-adjusted warfarin in patients with cerebral venous thrombosis
Saturday 20 October, 11:30 - 11:50, HALL B
Session code: AWA03
Session title: Award lectures & late breaking trials
Presentation number: 101
Please click on the following link for ‘Notes to Editors’ and ‘References’: http://www.boehringer-ingelheim.com/press-release/Results-from-two-Pradaxa-trials-to-be-presented-at-WSC
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. It is directed to the international audience outside Germany. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181015005075/en/
Media + PR
Phone: +49 6132 77 182085
Mobile: +49 151 44061760
Fax: +49 6132 77 6601